Evotec will identify hit molecules for Biogen Idec
Developer of novel small molecule drugs, Evotec AG has entered into a research agreement with biopharmaceutical company Biogen Idec, headquartered in Cambridge, Mass., US.
Evotec will use its expertise and technologies in protein production, assay development and high throughput screening to identify hit molecules for Biogen Idec.
Under the agreement Evotec will screen a target selected by Biogen Idec with the option to add further targets as agreed. Evotec will provide Biogen Idec with access to its full range of screening technologies and diverse library of high quality compounds and will use its expertise in protein production and assay development to develop new assays for the target.
Dr Mark Ashton, Evotec's EVP, business development said: "We believe that the quality of future drug candidates is very much dependant on the identification of high quality starting points. To this end we have established a platform of screening technologies that have been proven to identify high-class hit molecules. We are looking forward to working with Biogen Idec and identifying interesting hit compounds for them."
Evotec has built a platform of hit finding technologies that allow it to screen challenging targets and identify new classes of hit compounds that can be progressed towards new treatments for various diseases..
No financial details are disclosed.